6. CHINDRIS A M, DIEHL N N, CROOK J E, et al. Undetectable sensitive serum thyroglobulin (<0.1ng/ml) in 163 patients with follicular cell-derived thyroid cancer:results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up[J]. J Clin Endocrinol Metab, 2012, 97(8):2714-2723.
[3]
7. MIZRACHI A, FEINMESSER R, BACHAR G, et al. Value of ultrasound in detecting central compartment lymph node metastases in differentiated thyroid carcinoma[J]. Eur Arch Otorhinolaryngol, 2013.
[4]
9. HONG C M, AHN B C, JEONG S Y, et al. Distant metastatic lesions in patients with differentiated thyroid carcinoma. clinical implications of radioiodine and FDG uptake[J]. Nuklearmedizin, 2013, 52(4):121-129.
[5]
12. SCHLVTER B, BOHUSLAVIZKI K H, BEYER W, et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan[J]. J Nucl Med, 2001, 42(1):71-76.
[6]
28. VERBURG F A, M？DER U, TANASE K, et al. Life expectancy is reduced in differentiated thyroid cancer patients≥45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients[J]. J Clin Endocrinol Metab, 2013, 98(1):172-180.
[7]
16. CABRERA M M, PASAMONTES P J, CARRERAS D J, et al. Diagnostic accuracy of 18F-FDG PET in residual or recurrent differentiated thyroid carcinoma with high thyroglobulin and negative 131-I whole-body scan[J].Rev Esp Med Nucl, 2007, 26(5):263-269.
[8]
1. ？SILBERSTEIN E B. The problem of the patient with thyroglobulin elevation but negative Iodine scintigraphy:the TENIS syndrome[J]. Semin Nucl Med, 2011, 41(2):113-120.
5. ADEDAPO K S, VANGU M D. Data on repeated (131)I-WB scans and the incidence of positive Tg and negative (131)I-WBS in DTC patients from a 24 months study[J]. Hell J Nucl Med, 2011, 14(2):131-134.
[11]
10. VURAL G U, AKKAS B E, ERCAKMAK N, et al. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels:correlation with clinical and histopathologic characteristics and long-term follow-up data[J]. Clin Nucl Med, 2012, 37(10):953-959.
[12]
11. OZKAN E, ARAS G, KUCUK N O. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results[J]. Clin Nucl Med, 2013, 38(5):326-331.
[13]
13. NA S J, YOO IER, O J H, et al. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan:evaluation by thyroglobulin level[J]. Ann Nucl Med, 2012, 26(1):26-34.
[14]
14. WANG W, LARSON S M, TUTTLE R M, et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive Iodine[J]. Thyroid, 2001, 11(12):1169-1175.
[15]
15. BANNAS P, DERLIN T, GROTH M, et al. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?[J]. Ann Nucl Med, 2012, 26(1):77-85.
19. BASU S, ABHYANKAR A, ASOPA R, et al. A logical levothyroxine dose individualization:optimization approach at discharge from radioiodine therapy ward and during follow-up in patients of differentiated thyroid carcinoma:balancing the risk based strategy and the practical issues and challenges:experience and views of a large volume referral centre in India[J]. Indian J Nucl Med, 2013, 28(1):1-4.
[19]
20. SCHLUMBERGER M, ARCANGIOLI O, PIEKARSKI J D, et al. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays[J]. J Nucl Med, 1988, 29(11):1790-1794.
[20]
21. SINHA P, CONRAD G R, WEST H C. Response of thyroglobulin to radioiodine therapy in thyroglobulin-elevated negative iodine scintigraphy (TENIS) syndrome[J]. Anticancer Res, 2011, 31(6):2109-2112.
[21]
22. GONZáLEZ C, AULINAS A, COLOM C, et al. Thyroglobulin as early prognostic marker to predict remission at 18-24 months in differentiated thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2013.
[22]
23. CHAO M. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan[J]. Clin Oncol (R Coll Radiol), 2010, 22(6):438-447.
[23]
24. DOBRENIC M, HUIC D, ZUVIC M, et al. Usefulness of low iodine diet in managing patients with differentiated thyroid cancer-initial results[J]. Radiol Oncol, 2011, 45(3):189-195.
26. LI W, AIN K B. Human sodium-iodide symporter (hNIS) gene expression is inhibited by a trans-active transcriptional repressor, NIS-repressor, containing PARP-1 in thyroid cancer cells[J]. Endocr Relat Cancer, 2010, 17(2):383-398.
[26]
27. AL-HUMADI H, ZARROS A, AL-SAIGH R, et al. Genetic basis and gene therapy trials for thyroid cancer[J]. Cancer Genomics Proteomics, 2010, 7(1):31-49.
[27]
3. SONG H J, XUE Y L, QIU Z L, et al. Uncommon metastases from differentiated thyroid carcinoma[J]. Hell J Nucl Med, 2012, 15(3):233-240.
[28]
8. PALANISWAMY S S, SUBRAMANYAM P. Diagnostic utility of PETCT in thyroid malignancies:an update[J]. Ann Nucl Med, 2013, 27(8):681-693.
